Arcus Biosciences estimates ~$694M cash and securities

The preliminary balance remains subject to completion of closing procedures and may differ from the company’s actual September 30 position.

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) estimated that it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The preliminary, unaudited estimate is based on information available to management as of October 21, 2026, and remains subject to completion of financial closing procedures, including management reviews; it may differ from the actual September 30 balance. Ernst & Young LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to the preliminary data and expressed no opinion or other form of assurance on it.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Key Figures

Cash, cash equivalents and marketable securities: Approximately $694.0 million

1 metrics

Cash, cash equivalents and marketable securities Approximately $694.0 million Preliminary estimate as of September 30, 2026

Key Terms

marketable securities, financial closing procedures, generally accepted accounting principles

3 terms

marketable securities financial

"cash, cash equivalents and marketable securities"

Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.

financial closing procedures financial

"subject to completion of the Company’s financial closing procedures"

generally accepted accounting principles financial

"statements prepared in accordance with generally accepted accounting principles"

Generally accepted accounting principles (GAAP) are a standardized set of rules and practices companies use to record and report their financial results, like a common recipe so dishes from different cooks can be fairly compared. Investors rely on GAAP because it makes company earnings, assets and liabilities consistent and transparent across businesses, helping them compare performance, spot risks, and make informed decisions about buying or selling stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did RCUS estimate it had on September 30, 2026?

Arcus Biosciences estimated approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The preliminary, unaudited estimate remains subject to completion of financial closing procedures and may differ from the actual balance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 04:10 PM EDT Accepted by SEC EDGAR 10/21/2026 - 04:09 PM EDT Learn about SEC filing dates

false 0001724521 0001724521 2026-10-21 2026-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2026

Arcus Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38419		47-3898435
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3928 Point Eden Way Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 694-6200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share		RCUS		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the “Company”) as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of the Company’s financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and marketable securities balance set forth above reflects the Company’s preliminary estimate with respect to such information, based on information currently available to management, and may vary from its actual financial position as of September 30, 2026. Further, this preliminary estimate is not a comprehensive statement or estimate of its financial results or financial condition as of September 30, 2026. The unaudited preliminary cash, cash equivalents and marketable securities balance included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company’s management. Ernst & Young LLP, the Company’s independent registered public accounting firm, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. It is possible that the Company may identify items that require it to make adjustments to the financial information set forth above. This preliminary estimate should not be viewed as a substitute for financial statements prepared in accordance with generally accepted accounting principles in the United States, and it is not necessarily indicative of the balance to be achieved in any future period. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of September 30, 2026.

The information furnished under this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				ARCUS BIOSCIENCES, INC.
Date: October 21, 2026				By:		/s/ Terry Rosen, Ph. D.
						Terry Rosen, Ph.D.
						Chief Executive Officer
						(Principal Executive Officer)

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB